Abu Dhabi’s Mubadala Joins WHOOP’s $575 Million Raise

Mubadala Builds Presence in Data-Driven Health

The investment forms part of WHOOP’s Series G round, which values the U.S.-based wearable technology company at approximately $10.1 billion and brings together a mix of sovereign wealth funds, healthcare institutions, and global investors. The round was led by Collaborative Fund and included participation from Qatar Investment Authority, Abbott, Mayo Clinic, and other institutional and strategic backers.

For Mubadala, the deal reflects a broader strategy that has been quietly taking shape over the past several years, allocating capital toward sectors positioned at the intersection of healthcare, technology, and long-term demographic shifts.

Unlike traditional healthcare investments focused on hospitals or pharmaceuticals, this move centers on preventative and personalized care, an area increasingly shaped by continuous data collection and artificial intelligence. WHOOP’s platform, which tracks metrics such as sleep, recovery, and physical strain, is designed to shift healthcare from reactive treatment to proactive management, a model that aligns closely with Mubadala’s long-term investment thesis.

A Growing Focus on Preventive Healthcare

The participation of Gulf-based investors in the round is notable not only for its scale but also for what it signals about the region’s evolving role in global capital markets. Alongside Mubadala, both Qatar Investment Authority and 2PointZero Group joined the funding, highlighting how sovereign wealth funds across the Gulf are becoming more active in shaping emerging industries rather than simply allocating capital passively.

Gulf Capital Plays a Growing Role in Health Tech

This shift is increasingly visible in sectors such as health technology, where long-term returns are tied not just to financial performance but also to structural changes in how healthcare is delivered. Rising global healthcare costs, aging populations, and increasing awareness of preventative care are driving demand for platforms that can offer real-time, personalized insights.

WHOOP’s growth trajectory reflects that demand. The company now reports more than 2.5 million members globally and saw bookings grow by over 100% year-over-year in 2025, reaching a run rate of approximately $1.1 billion.

Mubadala’s investment in companies like WHOOP provides exposure to a category that sits at the convergence of consumer technology, medical innovation, and data analytics. It also complements the fund’s existing portfolio across life sciences and advanced healthcare, where the focus has increasingly shifted toward scalable, technology-enabled solutions.

WHOOP Targets GCC Expansion with New R&D Plans

The investment also carries a regional dimension. WHOOP has identified the Gulf as a key growth market and is actively expanding its presence across the GCC, including plans to establish WHOOP Labs Doha, its first international research and development facility.

That expansion is not happening in isolation. The Gulf region has been positioning itself as a hub for health innovation, supported by government-led initiatives, growing healthcare infrastructure, and increasing adoption of digital health solutions. For companies like WHOOP, the region offers both a consumer base and institutional partnerships that can accelerate adoption.

Mubadala’s perspective highlights a strategic overlap between investment and ecosystem development. By backing companies expanding into the region, the fund is not only deploying capital globally but also helping to anchor new technologies within local markets.

The structure of the funding round further reinforces this dynamic. In addition to sovereign wealth funds and institutional investors, the round included participation from major healthcare players such as Abbott and Mayo Clinic, as well as high-profile individual investors including professional athletes.

This blend of capital sources reflects the evolving nature of health technology, where credibility is shaped not just by financial backing but also by clinical validation and real-world usage among elite performers. WHOOP has built its brand around performance optimization, but its broader ambition is to establish a comprehensive health platform capable of monitoring and improving long-term wellbeing.

Will Ahmed, Founder and CEO of WHOOP, said: “Our raise brings together the world’s most sophisticated investors, leading health institutions, and iconic global athletes behind the mission to unlock human performance and healthspan. We are building the personal health platform that people use to improve their health and livelihood.”

Investors like Mubadala see that vision aligning with a broader structural shift in healthcare, where data becomes central to both prevention and treatment. As advances in AI and biometric monitoring continue to evolve, platforms like WHOOP are positioning themselves as part of a new layer of infrastructure within the healthcare ecosystem.

The timing of the investment also reflects broader market conditions. While some areas of technology have seen more cautious capital deployment in recent years, health and wellness platforms tied to measurable outcomes continue to attract strong investor interest. The combination of recurring subscription models, expanding user bases, and increasing integration with healthcare systems has made the sector more resilient compared to other segments of consumer technology.

In that context, Mubadala’s participation in WHOOP’s latest funding round can be seen as both a continuation of its existing strategy and a signal of where future capital allocation may be heading. Rather than focusing solely on traditional healthcare assets, the fund is increasingly targeting platforms that sit upstream, where data, behavior and technology intersect.